Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.
| 0.008 | |
| 0.008 | |
| - | |
| 0.008 | |
| 0.008 | |
| 0.0011-0.06 | |
| 57 767 | |
| 7 221 K | |
| 132 K | |
| -0.8278 | |
| 0.251 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Data will be instrumental in upcoming Phase 2 clinical trial of MLR-1023, Adhera’s novel Type 1 Diabetes drug candidateCompany moving forward with application to transition from OTC to NASDAQ Baton...
Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
